An interventional study of Bupivacaine 0.25% and Bupivacaine 0.25% in Gynecologic Laparoscopic Surgery, Postoperative Pain and Recovery Outcomes, sponsored by Usama Ahmed Elsaeed Salem, MD. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-06-22.
Sponsored by Usama Ahmed Elsaeed Salem, MD · Not applicable, Interventional, and Treatment
Among 362 studies testing bupivacaine in Pain, Postoperative — 55 open to participants now, 58 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 362 studies testing bupivacaine in Pain, Postoperative, this one is the 125th largest by enrollment, is one of 31 that started in 2024, is one of 109 with no phase, and was the 318th registered.
5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.
This study's enrollment of 90 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →55 of the 362 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Each count lists the studies.
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 241 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →362 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 31 started in 2024.
Median enrollment 70 across the 362 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
46 of 362 have an industry lead sponsor. The 10 most frequent:
Usama Ahmed Elsaeed Salem, MD is the lead sponsor of 2 studies on the registry; none are open to participants now.
Usama Ahmed Elsaeed Salem, MD has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
21 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Among the 362 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
This is a randomized, double-blind, controlled clinical trial evaluating the efficacy of local anesthetic (LA) in reducing postoperative pain in patients undergoing gynecologic laparoscopic surgery. Ninety participants will be randomly assigned into three equal groups: Group A will receive LA injection at the port site, Group B will receive intraperitoneal LA injection, and Group C will serve as the control group with no LA intervention. Postoperative pain will be assessed and compared among the three groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants aged 18 to 60 years
Scheduled for elective gynecological laparoscopic procedures, including:
Evaluation for primary or secondary infertility
Assessment of suspected uterine pathology
Evaluation of Müllerian anomalies
Assessment of suspected tubal or peritoneal pathology requiring diagnostic exploration.
Exclusion Criteria:
Known allergy or to local anesthetics (e.g., lidocaine or bupivacaine)
(BMI) ≥ 35 kg/m²
Severe hepatic or renal impairment
Chronic pain conditions requiring regular opioid use
History of major abdominal surgery
Refusal to provide or to enroll in the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a local anesthetic injection at the trocar/port sites of laparoscopic gynecologic surgery.
Drug: Bupivacaine 0.25%
Participants receive an intraperitoneal local anesthetic injection before removal of the laparoscopic instruments.
Drug: Bupivacaine 0.25%
Participants receive no local anesthetic injection during surgery.
At the end of gynecologic laparoscopic surgery and prior to trocar removal, 40 mL of Bupivacaine 0.25% is instilled intraperitoneal under direct vision to evaluate its analgesic effect.
Before trocar insertion in gynecologic laparoscopic surgery, 5 mL of Bupivacaine 0.25% is infiltrated subcutaneously at each trocar port site to assess its effect on postoperative pain.
Postoperative Pain score assessed using the Visual Analog Scale .
Postoperative pain will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate worse pain.
Time frame: 24 hours after surgery
Time to First Analgesic Request
Time frame: 24 hours after surgery
Total Analgesic Consumption
Time frame: within 24 hours after surgery
Patient Satisfaction Score
Patient satisfaction will be measured using a10- point Likert Scale, where 1 = Very Dissatisfied and 10 = Very Satisfied. Higher scores indicate greater satisfaction.
Time frame: 24 hours postoperatively
Length of Hospital Stay
The duration (in hours) from the end of surgery to the time of hospital discharge will be recorded. This outcome measures the efficiency of recovery and readiness for discharge.
Time frame: From end of surgery until hospital discharge assessed up to 7 days
Time to First Patient Ambulation
Time frame: Within 24 hours after surgery
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: 12 Months after publication of study results for a year.
Access criteria: Data will be shared upon reasonable request by contacting the corresponding author. Researchers must sign a data use agreement to access the data.
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine
Usama Ahmed Elsaeed Salem, MD